The patent expiration for Dupixent (dupilumab) is approaching, with multiple patents protecting the drug. The earliest anticipated patent expiration for Dupixent is around November 2026, based on the expiration of U.S. Patent No. 8,859,741, which covers methods of treating asthma with dupilumab [1]. However, other patents extend further into the future, with some expiring as late as 2036 [2].
When Can Generics or Biosimilars Enter the Market?
The actual market entry date for generic or biosimilar versions of Dupixent depends on several factors beyond the expiration of the primary patents. These include the resolution of any ongoing patent litigation, the successful development and FDA approval of biosimilar products, and the expiration of any market exclusivity granted by regulatory bodies [3]. The landscape of exclusivity and patent challenges can significantly influence the timeline for generic competition.
How Many Patents Protect Dupixent?
Dupixent is protected by a portfolio of patents. DrugPatentWatch.com tracks numerous patents related to dupilumab, covering different aspects of its use and formulation [1][2]. The exact number and specific expiration dates of these patents can be complex, as they include both composition of matter patents and patents on methods of use.
What Diseases Does Dupixent Treat?
Dupixent is approved to treat a range of inflammatory conditions. These include moderate-to-severe atopic dermatitis in adults and children, moderate-to-severe asthma in adults and children, and chronic rhinosinusitis with nasal polyposis in adults [4]. It is also indicated for eosinophilic esophagitis in adults and children aged 12 years and older, and for prurigo nodularis in adults [4].
Who Developed Dupixent?
Dupixent was developed by Regeneron Pharmaceuticals and Sanofi [4].
What are the Risks Associated with Dupixent?
Common side effects of Dupixent include injection site reactions, conjunctivitis, and oral herpes [4]. More serious side effects can involve allergic reactions and eye conditions [4]. Patients should discuss potential risks with their healthcare provider.